SCHEMBL23364628

SCHEMBL23364628

COC(=O)C1CC(OC(C)(C)C)CN1C(=O)OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
PDK1 Q15118 1/20 0.44
PDK2 Q15119 1/20 0.44
PDK3 Q15120 1/20 0.44
PDK4 Q16654 1/20 0.44
FKBP1A P62942 2/20 0.43
NPSR1 Q6W5P4 1/20 0.42
HTT P42858 2/20 0.42
MITF O75030 1/20 0.42
MAPT P10636 1/20 0.42
PREP P48147 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HTR2C P28335 1/20 0.41
CPB1 P15086 1/20 0.41
AGTR2 P50052 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17124819 1.00 POLB (0.46) POLBPDK1PDK2PDK3PDK4
SCHEMBL31751896 0.90 POLB (0.46) POLBPDK1PDK2PDK3PDK4
SCHEMBL2175331 0.90 POLB (0.46) POLBPDK1PDK2PDK3PDK4
SCHEMBL7347136 0.90 POLB (0.46) POLBPDK1PDK2PDK3PDK4
SCHEMBL6944593 0.90 POLB (0.46) POLBPDK1PDK2PDK3PDK4
SCHEMBL2177134 0.90 POLB (0.46) POLBPDK1PDK2PDK3PDK4
SCHEMBL13387830 0.89 POLB (0.45) POLBPDK1PDK2PDK3PDK4
SCHEMBL12234850 0.89 POLB (0.48) POLBPDK1PDK2PDK3PDK4
SCHEMBL2999647 0.89 POLB (0.49) POLBFKBP1ANPSR1HTTMITF
SCHEMBL9098331 0.89 POLB (0.49) POLBFKBP1ANPSR1HTTMITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025129104-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SIONNA THERAPEUTICS INC. (US) 2025-06-19 WO disclosed
US-20240002374-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY GENZYME CORPORATION 2024-01-04 US disclosed
EP-4058439-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY Genzyme Corporation (US) 2022-09-21 EP disclosed
CN-115003659-A 5-membered heteroaryl amino sulfonamides for the treatment of conditions mediated by a deficiency in CFTR activity 健赞公司 2022-09-02 CN disclosed
WO-2021097057-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY GENZYME CORPORATION (US) 2021-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002374-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY CFTR, PKD2, PKD1 POLB 1532/4885PDK1 2922/4885PDK2 2770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.